Jerini collaborates with leading pharmaceutical companies in the discovery and development of peptide-based drugs and for the commercialization of its products.  Discovery partnerships take advantage of the company’s Peptides-to-Drugs (P2D) technology platform to develop novel drug candidates for targets that are difficult to address using conventional drug development methods.  Jerini currently has collaborations with Alcon Research Ltd. and Baxter AG.

Alcon Research Ltd., the global leader in ophthalmological pharmaceuticals, and Jerini entered a multi-year collaboration agreement to develop both peptidomimetic and small molecule compounds addressing several undisclosed targets for the treatment of eye diseases.

See press release of January 19, 2005


Baxter AG and Jerini cooperate in a research program to develop a non-intravenous therapy for the treatment of hemophilia. Extensive in vitro and in vivo analyses have identified several synthetic lead molecules with promising pharmacological properties. The collaboration between Baxter and Jerini was initiated in 2001 and expanded in 2004, 2007 and again in 2008.

See press release of  January 10, 2008

See press release of  February 6, 2007
See press release of May 18, 2006